2.
Patients’ disposition
| Variables | No. of patients at various chidamide dose levels | ||
| 20 mg (N=3) | 25 mg (N=3) | 30 mg (N=4) | |
| DLT, dose-limiting toxicity; SAD, serious adverse event. | |||
| Combination cycles completed | |||
| 1 | 3 | 3 | 2 |
| 2 | 3 | 3 | 2 |
| 3 | 3 | 0 | 1 |
| 4 | 3 | 0 | 1 |
| Chidamide maintenance monotherapy | 2 | 0 | 0 |
| Reasons for discontinuation before cycle 4 (N=6) | |||
| Disease progression | 0 | 2 | 0 |
| DLT | 0 | 0 | 2 |
| SAD | 0 | 0 | 1 |
| Investigator's decision | 0 | 1 | 0 |